title: In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis.
abstract: Recent randomized trials have suggested that treatment with low molecular weight heparin (LMWH) improves survival of cancer patients with venous thromboembolism, as compared to treatment with unfractionated heparin (UFH). Experimental studies have shown that UFH has activities besides its anticoagulant function which may affect progression of malignancy, including stimulation of new blood vessel formation. In contrast, LMWH has been suggested to inhibit angiogenesis. In the present study, we compared quantitatively the effects of treatment with UFH, LMWH or placebo on the development of experimentally induced colon carcinoma metastases in rat liver and on tumor-associated angiogenesis. It is shown that UFH and LMWH in therapeutic dosages neither affect development of metastases nor tumor blood vessel formation in this animal model. These results indicate that heparins do not affect colon cancer metastasis in liver. Further studies in other animal models are required to establish the mechanisms by which heparins potentially affect cancer.
authors.affiliation: Academic Medical Center, University of Amsterdam, Department of Cell Biology and Histology, The Netherlands. s.m.smorenburg@amc.uva.nl
authors.forename: S M
authors.initials: SM
authors.lastname: Smorenburg
authors.forename: R
authors.initials: R
authors.lastname: Vink
authors.forename: M
authors.initials: M
authors.lastname: te Lintelo
authors.forename: W
authors.initials: W
authors.lastname: Tigchelaar
authors.forename: A
authors.initials: A
authors.lastname: Maas
authors.forename: H R
authors.initials: HR
authors.lastname: Büller
authors.forename: C J
authors.initials: CJ
authors.lastname: van Noorden
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology*; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009362:Neoplasm Metastasis / Q000517:prevention & control; D009389:Neovascularization, Pathologic; D051381:Rats
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin